Clinical Trial Update: A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH [Phase 3]

View source ↗

Summary

GlaxoSmithKline is conducting a Phase 3 study to evaluate the safety and tolerability of Efimosfermin Alfa Injection in participants with F2- or F3-stage MASH a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Efimosfermin Alfa (efimosfermin alfa)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Non-alcoholic Fatty Liver Disease | Phase 3 | Status: RECRUITING